Literature DB >> 9470085

Improvement of oxygenation induced by aerosolized prostacyclin in a preterm infant with persistent pulmonary hypertension of the newborn.

V Soditt1, C Aring, P Groneck.   

Abstract

OBJECTIVE: Case report on the effect of inhaled prostacyclin in a preterm infant (28 weeks gestational age) with respiratory distress syndrome complicated by marked hypoxemia due to persistent pulmonary hypertension of the newborn. Treatment with surfactant, hyperventilation, and elevation of systemic blood pressure had failed to improve oxygenation. MEASURES: A solution containing 10 micrograms PGI2/ml was aerosolized by the SPAG-2 aerosol-generator and then introduced into the afferent loop of the ventilatory circuit.
RESULTS: Oxygenation improved dramatically and worsened when aerosolization was withdrawn. Intravenous prostacyclin had no additional effect on oxygenation. We observed no side effects on blood pressure and no bleeding complications. Inhalation was stopped after 40 hours and the baby was successfully weaned from the ventilator after 108 hours.
CONCLUSION: Inhaled PGI2 had a beneficial effect on the oxygenation of a preterm neonate with persistent pulmonary hypertension of the newborn.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9470085     DOI: 10.1007/s001340050498

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  20 in total

1.  Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn.

Authors:  J P Kinsella; S R Neish; E Shaffer; S H Abman
Journal:  Lancet       Date:  1992-10-03       Impact factor: 79.321

2.  Persistent pulmonary hypertension in premature neonates with severe respiratory distress syndrome.

Authors:  F J Walther; M J Benders; J O Leighton
Journal:  Pediatrics       Date:  1992-12       Impact factor: 7.124

3.  In vitro performance of the small particle aerosol generator (SPAG-2).

Authors:  C J Newth; A R Clark
Journal:  Pediatr Pulmonol       Date:  1989

Review 4.  Prostacyclin and prostaglandin E1: molecular mechanisms and therapeutic utility.

Authors:  D M Kerins; R Murray; G A FitzGerald
Journal:  Prog Hemost Thromb       Date:  1991

5.  Pulmonary and systemic arterial pressure in hyaline membrane disease.

Authors:  J R Skinner; R J Boys; S Hunter; E N Hey
Journal:  Arch Dis Child       Date:  1992-04       Impact factor: 3.791

6.  Aerosolised prostacyclin in adult respiratory distress syndrome.

Authors:  D Walmrath; T Schneider; J Pilch; F Grimminger; W Seeger
Journal:  Lancet       Date:  1993-10-16       Impact factor: 79.321

7.  PGI2 aerosol versus nitric oxide for selective pulmonary vasodilation in hypoxic pulmonary vasoconstriction.

Authors:  M Welte; B Zwissler; H Habazettl; K Messmer
Journal:  Eur Surg Res       Date:  1993       Impact factor: 1.745

8.  Intratracheal administration of pulmonary vasodilator agents.

Authors:  M A D'Angeli; B W Goetzman
Journal:  Pediatr Pulmonol       Date:  1992-10

9.  Aerosolised prostacyclin for pulmonary hypertension in neonates.

Authors:  L Bindl; H Fahnenstich; U Peukert
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1994-11       Impact factor: 5.747

10.  Doppler assessment of pulmonary artery pressure and extrapulmonary shunting in the acute phase of hyaline membrane disease.

Authors:  N J Evans; L N Archer
Journal:  Arch Dis Child       Date:  1991-01       Impact factor: 3.791

View more
  15 in total

Review 1.  Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents.

Authors:  Nicolas F M Porta; Robin H Steinhorn
Journal:  Clin Perinatol       Date:  2012-03       Impact factor: 3.430

Review 2.  Controversies in the identification and management of acute pulmonary hypertension in preterm neonates.

Authors:  Regan E Giesinger; Kiran More; Jodie Odame; Amish Jain; Robert P Jankov; Patrick J McNamara
Journal:  Pediatr Res       Date:  2017-10-04       Impact factor: 3.756

Review 3.  Persistent pulmonary hypertension of the newborn: pathogenesis, etiology, and management.

Authors:  Enrique M Ostrea; Esterlita T Villanueva-Uy; Girija Natarajan; Herbert G Uy
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 4.  Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn.

Authors:  Batoule H Majed; Raouf A Khalil
Journal:  Pharmacol Rev       Date:  2012-06-07       Impact factor: 25.468

Review 5.  Pharmacotherapy for pulmonary hypertension.

Authors:  Robin H Steinhorn
Journal:  Pediatr Clin North Am       Date:  2012-08-26       Impact factor: 3.278

6.  Update on PPHN: mechanisms and treatment.

Authors:  Jayasree Nair; Satyan Lakshminrusimha
Journal:  Semin Perinatol       Date:  2014-03       Impact factor: 3.300

7.  Milrinone enhances relaxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn.

Authors:  Satyan Lakshminrusimha; Nicolas F M Porta; Kathryn N Farrow; Bernadette Chen; Sylvia F Gugino; Vasanth H Kumar; James A Russell; Robin H Steinhorn
Journal:  Pediatr Crit Care Med       Date:  2009-01       Impact factor: 3.624

8.  Diagnosis and treatment of pulmonary hypertension in infancy.

Authors:  Robin H Steinhorn
Journal:  Early Hum Dev       Date:  2013-09-29       Impact factor: 2.079

9.  Aerosolized PGE1: a selective pulmonary vasodilator in neonatal hypoxemic respiratory failure results of a Phase I/II open label clinical trial.

Authors:  Beena G Sood; Virginia Delaney-Black; Jacob V Aranda; Seetha Shankaran
Journal:  Pediatr Res       Date:  2004-08-04       Impact factor: 3.756

Review 10.  Life-threatening PPHN refractory to nitric oxide: proposal for a rational therapeutic algorithm.

Authors:  Feriel Fortas; Matteo Di Nardo; Nadya Yousef; Marc Humbert; Daniele De Luca
Journal:  Eur J Pediatr       Date:  2021-06-06       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.